Estimating steady state desipramine levels in noninstitutionalized elderly patients using single dose disposition...

Area of Science:

• Pharmacokinetics
• Geriatric Medicine
• Psychiatry

Background:

• Elderly patients often exhibit altered drug metabolism and pharmacokinetics.
• Accurate prediction of drug levels is crucial for effective treatment and minimizing adverse effects in this population.
• Desipramine is a commonly prescribed antidepressant for elderly individuals with depression.

Purpose of the Study:

• To evaluate the utility of single oral dose clearance data in predicting steady-state plasma levels of desipramine in elderly patients.
• To compare the predictive accuracy of single-dose clearance versus single-dose plasma levels for desipramine.
• To determine the mean half-life of desipramine in a cohort of noninstitutionalized elderly depressed patients.

Main Methods:

• Calculation of desipramine clearance from single oral dose data.
• Prediction of steady-state plasma levels based on single-dose clearance.
• Comparison of predicted levels with observed steady-state levels.
• Measurement of desipramine plasma levels 20 hours after a single oral dose.
• Determination of the mean half-life of desipramine in the study group.

Main Results:

• Observed steady-state plasma levels of desipramine showed a strong correlation (r = 0.967, p < 0.0005) with levels predicted from single-dose clearances.
• Plasma levels obtained 20 hours after a single oral dose did not correlate well with predicted steady-state levels (r = 0.24, p > 0.2).
• The mean half-life of desipramine in elderly patients (mean age, 72 years) was 20.9 hours, which is shorter than previously reported values for imipramine in elderly patients.

Conclusions:

• Single oral dose clearance is a reliable method for predicting steady-state desipramine levels in elderly depressed patients.
• This technique provides a precise criterion for assessing early drug compliance and adjusting dosing regimens.
• The findings suggest that desipramine's pharmacokinetic profile in the elderly may differ from other tricyclic antidepressants like imipramine.